Skip to main content

Inaccurately Reported Statin Use Affects the Assessing of Lipid Profile Measures and Their Association with Coronary Artery Disease Risk.

Publication ,  Journal Article
Ivanova, AA; Gardner, MS; Kusovschi, JD; Parks, BA; Schieltz, DM; Bareja, A; McGarrah, RW; Kraus, WE; Kuklenyik, Z; Pirkle, JL; Barr, JR
Published in: Clin Chem
March 2, 2024

BACKGROUND: Lipid profiling is central for coronary artery disease (CAD) risk assessment. Nonadherence or unreported use of lipid-lowering drugs, particularly statins, can significantly complicate the association between lipid profile measures and CAD clinical outcomes. By combining medication history evaluation with statin analysis in plasma, we determined the effects of inaccurately reported statin use on lipid profile measures and their association with CAD risk. METHODS: We compared medication history of statin use with statin concentration measurements, by liquid chromatography-tandem mass spectrometry, in 690 participants undergoing coronary angiography (63 ± 11 years of age). Nominal logistic regression was employed to model CAD diagnosis with statin measurements, phenotypic, and lipid profile characteristics. RESULTS: Medication history of statin use was confirmed by statin assay for 81% of the patients. Surprisingly, statins were detected in 46% of patients without statin use records. Nonreported statin use was disproportionately higher among older participants. Stratifying samples by statin history resulted in underestimated LDL-lipid measures. Apolipoprotein B concentrations had a significant inverse CAD association, which became nonsignificant upon re-stratification using the statin assay data. CONCLUSIONS: Our study uncovered prominent discrepancies between medication records and actual statin use measured by mass spectrometry. We showed that inaccurate statin use assessments may lead to overestimation and underestimation of LDL levels in statin user and nonuser categories, exaggerating the reverse epidemiology association between LDL levels and CAD diagnosis. Combining medication history and quantitative statin assay data can significantly improve the design, analysis, and interpretation of clinical and epidemiological studies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Chem

DOI

EISSN

1530-8561

Publication Date

March 2, 2024

Volume

70

Issue

3

Start / End Page

528 / 537

Location

England

Related Subject Headings

  • Risk Factors
  • Risk Assessment
  • Middle Aged
  • Lipids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General Clinical Medicine
  • Coronary Artery Disease
  • Coronary Angiography
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ivanova, A. A., Gardner, M. S., Kusovschi, J. D., Parks, B. A., Schieltz, D. M., Bareja, A., … Barr, J. R. (2024). Inaccurately Reported Statin Use Affects the Assessing of Lipid Profile Measures and Their Association with Coronary Artery Disease Risk. Clin Chem, 70(3), 528–537. https://doi.org/10.1093/clinchem/hvad223
Ivanova, Anna A., Michael S. Gardner, Jennifer D. Kusovschi, Bryan A. Parks, David M. Schieltz, Akshay Bareja, Robert W. McGarrah, et al. “Inaccurately Reported Statin Use Affects the Assessing of Lipid Profile Measures and Their Association with Coronary Artery Disease Risk.Clin Chem 70, no. 3 (March 2, 2024): 528–37. https://doi.org/10.1093/clinchem/hvad223.
Ivanova AA, Gardner MS, Kusovschi JD, Parks BA, Schieltz DM, Bareja A, et al. Inaccurately Reported Statin Use Affects the Assessing of Lipid Profile Measures and Their Association with Coronary Artery Disease Risk. Clin Chem. 2024 Mar 2;70(3):528–37.
Ivanova, Anna A., et al. “Inaccurately Reported Statin Use Affects the Assessing of Lipid Profile Measures and Their Association with Coronary Artery Disease Risk.Clin Chem, vol. 70, no. 3, Mar. 2024, pp. 528–37. Pubmed, doi:10.1093/clinchem/hvad223.
Ivanova AA, Gardner MS, Kusovschi JD, Parks BA, Schieltz DM, Bareja A, McGarrah RW, Kraus WE, Kuklenyik Z, Pirkle JL, Barr JR. Inaccurately Reported Statin Use Affects the Assessing of Lipid Profile Measures and Their Association with Coronary Artery Disease Risk. Clin Chem. 2024 Mar 2;70(3):528–537.

Published In

Clin Chem

DOI

EISSN

1530-8561

Publication Date

March 2, 2024

Volume

70

Issue

3

Start / End Page

528 / 537

Location

England

Related Subject Headings

  • Risk Factors
  • Risk Assessment
  • Middle Aged
  • Lipids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General Clinical Medicine
  • Coronary Artery Disease
  • Coronary Angiography
  • Aged